Medivir Puts $90M Bid on the Table for BioPhausia
By Cormac Sheridan
Wednesday, April 13, 2011
Although it does not expect to launch its hotly anticipated hepatitis C drug TMC435 until late 2013, at the earliest, Medivir AB is putting in place the supporting infrastructure now, by bidding to acquire specialty pharma firm BioPhausia AB, in a cash-and-shares deal valued at SEK565 million (US$90.1 million).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.